<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660853</url>
  </required_header>
  <id_info>
    <org_study_id>13/LO/1198</org_study_id>
    <nct_id>NCT02660853</nct_id>
  </id_info>
  <brief_title>Exacerbations in Severe Asthma Patients: Mechanisms and Biomarkers</brief_title>
  <official_title>Exacerbations in Severe Asthma Patients: Mechanisms and Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate exacerbations in severe asthma with regard to
      symptoms, lung function, aetiology and biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited from the Severe Asthma Clinics at Royal Brompton Hospital. At the
      first visit the investigators will enrol and characterise patients. This will involve asking
      patients to keep a diary record of PEFR(Peak Expiratory Flow Rate), spirometry, symptom
      scores, use of beta-agonist reliever and other treatments for 2 weeks. Bloods tests will be
      taken for markers of systemic inflammation. Markers of oxidative stress will be measured in
      blood, exhaled breath condensate (EBC) and urine: malondialdehyde (MDA) and 8-isoprostanes.
      Nitric oxide (NO) levels in exhaled breath will be measured measured twice daily for 2 weeks
      using a portable hand-held NO meter. If spontaneous sputum is not available, sputum will be
      induced using ultrasonic nebulization of isotonic saline. Profile of inflammatory cells,
      cytokines in supernatants, bacteriological culture and microbiome analysis will be measured
      in the sputum. Patients will be observed over 12 months during which time the number of
      exacerbations will be recorded on basis of objective measures with evaluation of ACQ (Asthma
      Control Questionnaire), daily morning and evening PEF (Peak Expiratory Flow). At the earliest
      onset of exacerbation, the patient will be requested to contact the Asthma Research Unit.
      Patients will then be asked to attend the laboratory where similar tests to the first visit
      will be performed. For other exacerbations not studied, the patient will be asked to keep a
      detailed diary record of symptoms with severity scoring and spirometric and PEF measurements
      (Exacerbation Diary) over a period of 2 weeks after onset of exacerbation.

      As patients with severe asthma are usually very well experienced in what the symptoms of
      exacerbations are, they will therefore be asked to recognise their own exacerbations. Each
      patient has their own way of recognising an exacerbation and the investigators will discuss
      this with each patient and try and establish whether an earlier warning signal is possible.
      Patients will be asked to record their symptoms and lung function as soon as they feel the
      onset of an exacerbation, since exacerbations are recognised by the patient as events that
      are 'clinically identified by being outside the patient's usual range of day-to-day
      variation'. The patient will receive or administer treatments for the exacerbation as usual
      without interference from the Research Team except for starting any antibiotic therapies,
      which will be started (if prescribed) as soon as the visit studies have been completed. Those
      who have been hospitalized will not be studied, and only those who can attend the Clinical
      Research Unit will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Predicted FEV1</measure>
    <time_frame>Baseline Visit, 12 months</time_frame>
    <description>From date of screening visit until date of first asthma exacerbation visit Percent predicted Forced Expiratory Volume in First Second</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled Breath Condensate</measure>
    <time_frame>Baseline Visit, 12 months</time_frame>
    <description>pH and free Iron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Oxidative Stress in Urine</measure>
    <time_frame>Baseline Visit, 12 months</time_frame>
    <description>malondialdehyde (MDA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Oxidative Stress in Urine</measure>
    <time_frame>Baseline Visit, 12 months</time_frame>
    <description>8-isoprostanes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Analysis</measure>
    <time_frame>From baseline visit and 12 months</time_frame>
    <description>Eosinophils as percentage of total count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCR for Respiratory Viruses</measure>
    <time_frame>Baseline Visit, 12 months</time_frame>
    <description>nasopharyngeal swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Microbiome</measure>
    <time_frame>Baseline Visit, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid Insensitivity in Peripheral Blood Mononuclear Cells</measure>
    <time_frame>Baseline Visit, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled Nitric Oxide</measure>
    <time_frame>Baseline Visit, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled Hydrogen Sulphide</measure>
    <time_frame>Baseline Visit, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Severe Asthma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FEV1</intervention_name>
    <description>Participants have FEV1 test</description>
    <arm_group_label>Severe Asthma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must be able to give informed consent. The definition of severe asthma
             will be on the basis of

               -  Uncontrolled asthma: three or more of the following features present in any week
                  in the previous 4 weeks:

                    -  Daytime symptoms more than twice per week

                    -  Any limitation of activities

                    -  Nocturnal symptoms once or more per week

                    -  Need for reliever treatment more than twice per week

                    -  Pre bronchodilator FEV1 &lt;80% predicted or personal best OR

               -  Frequent severe exacerbations (≥2 per year) OR

               -  Require prescription of daily or alternate day oral corticosteroids (OCS) to
                  achieve asthma control despite the prescription of high dose inhaled
                  corticosteroids (&gt;1000mcg fluticasone propionate daily or equivalent) or
                  maintenance oral corticosteroids plus a long acting beta agonist or one other
                  controller medication (for example anti-cholinergics, leukotriene receptor
                  antagonists or theophylline).

        Exclusion Criteria:

          -  • Current smoker, or Ex-smoker with a &gt;10 year pack history or having smoked within
             the past 6 months

               -  Significant alternative diagnoses that may mimic or complicate asthma, in
                  particular dysfunctional breathing, panic attacks, and overt psychosocial
                  problems (if these are thought to be the major problem rather than in addition to
                  severe asthma)

               -  Significant other primary pulmonary disorders in particular pulmonary embolism,
                  pulmonary hypertension, interstitial lung disease and lung cancer

               -  Subjects with emphysema and bronchiectasis should only be excluded if this is
                  thought to be the major pulmonary disorder rather than in addition to severe
                  asthma

               -  Diagnosis or current investigation of occupational asthma

               -  Any subjects currently participating, or having participated within 3 months of
                  the first dose in a study using a new molecular entity, or the first dose in any
                  other study investigating drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kian F Chung, MBBS MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biomedical research Unit, Royal Brompton Hospital, Sydney Street</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 2, 2015</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <results_first_submitted>September 13, 2019</results_first_submitted>
  <results_first_submitted_qc>October 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 31, 2019</results_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exacerbations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 21, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02660853/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Severe Asthma</title>
          <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines, Observational study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Severe Asthma</title>
          <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.9" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Predicted FEV1</title>
        <description>From date of screening visit until date of first asthma exacerbation visit Percent predicted Forced Expiratory Volume in First Second</description>
        <time_frame>Baseline Visit, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma</title>
            <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Predicted FEV1</title>
          <description>From date of screening visit until date of first asthma exacerbation visit Percent predicted Forced Expiratory Volume in First Second</description>
          <units>% of predicted value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline versus during exacerbation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.745</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exhaled Breath Condensate</title>
        <description>pH and free Iron</description>
        <time_frame>Baseline Visit, 12 months</time_frame>
        <population>No data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma</title>
            <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Breath Condensate</title>
          <description>pH and free Iron</description>
          <population>No data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Oxidative Stress in Urine</title>
        <description>malondialdehyde (MDA)</description>
        <time_frame>Baseline Visit, 12 months</time_frame>
        <posting_date>02/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Oxidative Stress in Urine</title>
        <description>8-isoprostanes</description>
        <time_frame>Baseline Visit, 12 months</time_frame>
        <posting_date>02/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Analysis</title>
        <description>Eosinophils as percentage of total count</description>
        <time_frame>From baseline visit and 12 months</time_frame>
        <population>Severe asthma at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma</title>
            <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Analysis</title>
          <description>Eosinophils as percentage of total count</description>
          <population>Severe asthma at baseline</population>
          <units>Percentage of total sputum counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.326</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCR for Respiratory Viruses</title>
        <description>nasopharyngeal swabs</description>
        <time_frame>Baseline Visit, 12 months</time_frame>
        <population>No data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma</title>
            <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>PCR for Respiratory Viruses</title>
          <description>nasopharyngeal swabs</description>
          <population>No data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Microbiome</title>
        <time_frame>Baseline Visit, 12 months</time_frame>
        <population>No data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma</title>
            <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Microbiome</title>
          <population>No data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corticosteroid Insensitivity in Peripheral Blood Mononuclear Cells</title>
        <time_frame>Baseline Visit, 12 months</time_frame>
        <population>No data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma</title>
            <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Corticosteroid Insensitivity in Peripheral Blood Mononuclear Cells</title>
          <population>No data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exhaled Nitric Oxide</title>
        <time_frame>Baseline Visit, 12 months</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma</title>
            <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Nitric Oxide</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exhaled Hydrogen Sulphide</title>
        <time_frame>Baseline Visit, 12 months</time_frame>
        <population>Data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Severe Asthma</title>
            <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Hydrogen Sulphide</title>
          <population>Data were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Severe Asthma</title>
          <description>Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Fan Chung</name_or_title>
      <organization>Imperial College London</organization>
      <phone>00442075947954</phone>
      <email>f.chung@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

